Literature DB >> 23347959

Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations.

Emil M deGoma1, Richard L Dunbar, Douglas Jacoby, Benjamin French.   

Abstract

BACKGROUND: Current cardiovascular risk assessment guidelines incorporate judicious use of C-reactive protein (CRP), carotid intima-media thickness (CIMT), and coronary artery calcium (CAC) in selected populations and describe threshold levels for higher and lower cardiovascular risk for each of the three risk refinement tests. However, the effect of these suggested thresholds of relative risk on absolute global risk remains uncertain.
METHODS: Systematic permutation of risk factors provided 10-year risk estimates using the Framingham risk score, equations derived from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Atherosclerosis Risk in Communities (ARIC) study, and the Reynolds risk score. Low-, high-, and very-high-risk values of CAC, CIMT, and hsCRP were defined as: 0, 100, 400 Agatston units; 25th percentile without plaque, 75th percentile without plaque, 75th percentile with plaque; and 1.0, 3.0, 7.0 mg/L.
RESULTS: Incorporation of low-, high-, and very-high-risk CAC values using the MESA risk score resulted in greater changes in absolute risk from the Framingham risk score than the addition of either CIMT or hsCRP values using the ARIC or Reynolds risk scores.
CONCLUSIONS: Although certain values of CAC, CIMT, and hsCRP have been similarly designated as low, high, or very-high risk, incorporation of these thresholds into validated risk equations yielded substantially different levels of absolute cardiovascular risk. Use of available risk equations may be advisable to calculate absolute risk rather than relying on risk-marker thresholds derived from relative risk estimates.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23347959     DOI: 10.1016/j.atherosclerosis.2012.12.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.

Authors:  Yelena Parfyonova; Irina Alekseeva; Olga Plekhanova; Alexander Deev; Elena Titaeva; Anatoly Dobrovolsky; Zufar Gabbasov; Anatoly Lyakishev; Vsevolod Tkachuk
Journal:  Heart Vessels       Date:  2013-09-22       Impact factor: 2.037

2.  Jujuboside A Ameliorates Myocardial Apoptosis and Inflammation in Rats with Coronary Heart Disease by Inhibiting PPAR-α Signaling Pathway.

Authors:  Chunfang Hu; Zhiyuan Zhang; Guixian Song; Li Zhu; Ruzhu Wang; Zhongbao Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-24       Impact factor: 2.650

Review 3.  Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis?

Authors:  A Purcarea; S Sovaila; A Gheorghe; G Udrea; V Stoica
Journal:  J Med Life       Date:  2014 Oct-Dec

Review 4.  Antioxidants and Cardiovascular Risk Factors.

Authors:  Daniela Pellegrino
Journal:  Diseases       Date:  2016-02-17

5.  Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.

Authors:  Richard L Dunbar; Daniel Gaudet; Michael Davidson; Martin Rensfeldt; Hong Yang; Catarina Nilsson; Mats Kvarnström; Jan Oscarsson
Journal:  Lipids Health Dis       Date:  2020-05-30       Impact factor: 3.876

6.  Omega-3 Fatty Acids in Erythrocyte Membranes as Predictors of Lower Cardiovascular Risk in Adults without Previous Cardiovascular Events.

Authors:  Gustavo Henrique Ferreira Gonçalinho; Geni Rodrigues Sampaio; Rosana Aparecida Manólio Soares-Freitas; Nágila Raquel Teixeira Damasceno
Journal:  Nutrients       Date:  2021-06-03       Impact factor: 5.717

7.  Impaired Oxidative Status Is Strongly Associated with Cardiovascular Risk Factors.

Authors:  E Brunelli; D La Russa; D Pellegrino
Journal:  Oxid Med Cell Longev       Date:  2017-12-12       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.